PPT-Boceprevir in Treatment Naive

Author : min-jolicoeur | Published Date : 2017-09-03

SPRINT2 Phase 3 Treatment Naive Treatment Naïve Source Poordad F et al N Engl J Med 20113641195206 Boceprevir for TreatmentNaïve HCV Genotype 1 SPRINT 2

Presentation Embed Code

Download Presentation

Download Presentation The PPT/PDF document "Boceprevir in Treatment Naive" is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.

Boceprevir in Treatment Naive: Transcript

SPRINT2 Phase 3 Treatment Naive Treatment Naïve Source Poordad F et al N Engl J Med 20113641195206 Boceprevir for TreatmentNaïve HCV Genotype 1 SPRINT 2 Trial Study Design. for Patients with Prior Failure to PEG + RIB. PROVIDE. Phase . 3. Treatment. . Experienced. Vierling. JM, . et al. . J . Hepatol. . 2013;Dec 19 [. Epub. ahead of print].. Source: . Vierling. . JM, et al. J . RESPOND-2. Phase . 3. Treatment. . Experienced. Bacon BR, et al. N . Engl. J Med. 2011;364:1207-17.. Source: . Bacon BR, et al. N Engl J Med. 2011;364:1207-17.. Boceprevir for Retreatment of HCV Genotype 1 Infection . Morris Sherman MD . BCh. PhD FRCP(C) . Associate Professor of Medicine. University of Toronto. Protease Inhibitors . in Chronic . Hepatitis C:. An . Update. Chapter 2. – Important Hepatitis C Protease Inhibitor Drug Interactions in Mono and HIV . thalassaemia. . Where . are we now?. Telaprevir . and . boceprevir. harbingers . of important . treatment advance. Improved response rates . observed : . naive . and . experienced patients. SVR > 70. Out With the Old, In With the New. Current Standard of Care. NEUTRINO and FISSION. . SOF + RBV ± pegIFN for Treatment-naive Patients. NEUTRINO and FISSION. . SOF + RBV ± pegIFN for Treatment-naive Patients. Morris Sherman MD . BCh. PhD FRCP(C) . Associate Professor of Medicine. University of Toronto. Protease Inhibitors . in Chronic . Hepatitis C:. An . Update. COMPLETE SLIDE DECK (Chapters 1 – 6). November 2012. Morris Sherman MD . BCh. PhD FRCP(C) . Associate Professor of Medicine. University of Toronto. Protease Inhibitors . in Chronic . Hepatitis C:. An . Update. Chapter 5. – Case Study: Cirrhosis. November 2012. Mark S. Sulkowski, MD. Medical Director, Viral Hepatitis Center. Divisions of Infectious Diseases and Gastroenterology/Hepatology. Johns Hopkins University School of Medicine. Baltimore, Maryland. Treatment-Naive Data . with PEG + RBV in Genotype 1. SPRINT. -1. Phase . 2. Treatment. . Naïve. Kwo. PY, et al. Lancet. 2010;376:705-16.. Source: . Kwo PY, et al. Lancet. 2010;376:705-16. .. Boceprevir . for Treatment-Naïve HCV Genotype 1. . Case. 47-Year-Old . Man With Asymptomatic HIV Infection. Case (cont). Initial Clinical Presentation. Laboratory Results. HepaScore. ®. A Composite Biomarker Panel for Liver Fibrosis. Hepatic Steatosis in Patients With HIV/HCV Coinfection. Créteil, France. Paris, 30 January 2012. Triple therapy today:. Safety management in clinical practice. Telaprevir. placebo-controlled Phase II/III studies: . summary of AEs during . telaprevir. /placebo phase. Mark Sulkowski, . MD. Professor of Medicine. Medical Director, Viral Hepatitis Center . Johns Hopkins University. Baltimore Maryland USA. Liver disease is the second leading specific causes of death amongst HIV-positive individuals in the D:A:D study. in Hepatitis C . Paris . Februari. 2012. Ola . Weiland. Karolinska Institutet. Stockholm, Sweden. New major adverse events with PIs. . Exanthema for TVR. . Prolonged anemia with BOC. Telaprevir. Illuminate study. SPRINT. -1. Phase . 2. Treatment. . Naïve. Kwo. PY, et al. Lancet. 2010;376:705-16.. Source: . Kwo PY, et al. Lancet. 2010;376:705-16. .. Boceprevir . for Treatment-Naïve HCV Genotype 1. SPRINT.

Download Document

Here is the link to download the presentation.
"Boceprevir in Treatment Naive"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.